医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ClearB Therapeutics Announces Acceptance of Abstract Highlighting New Pre-Clinical Hepatitis B Data as a Poster Presentation at EASL 2021

2021年06月22日 AM01:23
このエントリーをはてなブックマークに追加


 

CONCORD, Mass. & MELBOURNE, Australia

ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled ‘A novel therapeutic vaccine achieves functional cure in a mouse model of chronic hepatitis B’ was accepted for poster presentation at the European Association for the Study of the Liver (EASL) Digital International Liver Congress (ILC), taking place virtually June 23-26, 2021. The poster was also selected for inclusion in the ‘Best of ILC’ summary, which highlights the most noteworthy scientific contributions at this year’s meeting.

“We are excited to share our preclinical data with the Hepatitis B medical community as we move our therapeutic vaccine candidate toward the clinic,” said Aileen Rubio, PhD., Head of Research and Development for the company. ClearB Therapeutics Co-Founder and Clinical Advisory Board Chair Professor Stephen Locarnini, MBBS, PhD added, “Chronic Hepatitis B (CHB) infection is a significant world-wide disease burden that is likely to require use of combination therapies to achieve meaningful, sustained viral suppression. We believe that re-education of patients’ immune systems to break tolerance of their chronic HBV infections through co-administration of ClearB’s therapeutic vaccine could become an important component of such treatment regimens.”

Abstract Number: 853
Abstract Title: A novel therapeutic vaccine achieves functional cure in a mouse model of chronic hepatitis B 
Date: Wednesday, June 23, 2021 
Time: 8:00 AM CET (2:00 AM ET) 
Presenter Name: Dr. Renae Walsh, Senior Research Director, ClearB Therapeutics

For more information regarding EASL 2021 please visit https://easl.eu/event/the-international-liver-congress-2021/

About ClearB Therapeutics

ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B. For more information, please visit https://clearbtherapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210621005654/en/

CONTACT

Wendy Gabel

Kendall Investor Relations

wgabel@kendallir.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 研究人员利用Masimo Root®先进的多模式监测功能研究胸腔镜手术期间不同通气策略对脑氧合的影响
  • 2023 Japan Prize Laureates Announced
  • PHCと帝人ファーマ、「オスタバロ®皮下注カートリッジ 1.5mg」専用の電動式注入器「オスタバロ®インジェクター」を共同開発し発売開始
  • Philip Morris International Inc. (PMI) Announces Agreement to Extend and Deepen Collaboration With KT&G
  • 武田获得和黄医药的高选择性口服VEGFR1/2/3酪氨酸激酶抑制剂呋喹替尼的全球(中国以外)独家授权